Alto Neuroscience (ANRO) had its price target raised by Robert W. Baird from $22.00 to $41.00. They now have an "outperform" rating on the stock.
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
Alto Neuroscience (ANRO) had its price target raised by Wedbush from $13.00 to $22.00. They now have a "neutral" rating on the stock.
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Alto Neuroscience announces $120M private placement financing [Seeking Alpha]